BioCardia Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für BioCardia zu prognostizieren.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.7%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	None
Zuletzt aktualisiert	n/a

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable

May 14

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

Oct 12

BioCardia stock rises on contract for delivery products for BlueRock's cell therapies

Aug 24

Shareholders May Not Be So Generous With BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation And Here's Why

Jun 08

Is BioCardia (NASDAQ:BCDA) In A Good Position To Deliver On Growth Plans?

May 20

BioCardia issued U.S. patent for Helix Biotherapeutic Delivery system

Dec 30

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da BioCardia jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:BCDA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2024	0	-10	-9	-9	N/A
12/31/2023	0	-12	-10	-10	N/A
9/30/2023	1	-13	-11	-11	N/A
6/30/2023	0	-13	-11	-11	N/A
3/31/2023	1	-12	-10	-10	N/A
12/31/2022	1	-12	-11	-11	N/A
9/30/2022	1	-12	-11	-11	N/A
6/30/2022	2	-12	-11	-11	N/A
3/31/2022	1	-13	-12	-11	N/A
12/31/2021	1	-13	-10	-10	N/A
9/30/2021	1	-12	-11	-11	N/A
6/30/2021	0	-13	-12	-12	N/A
3/31/2021	0	-13	-11	-11	N/A
12/31/2020	0	-15	-12	-12	N/A
9/30/2020	0	-16	-12	-12	N/A
6/30/2020	0	-15	-10	-10	N/A
3/31/2020	1	-16	-10	-10	N/A
12/31/2019	1	-15	-10	-9	N/A
9/30/2019	1	-15	-10	-9	N/A
6/30/2019	0	-15	-10	-10	N/A
3/31/2019	1	-14	-11	-10	N/A
12/31/2018	1	-14	-11	-11	N/A
9/30/2018	1	-14	-10	-10	N/A
6/30/2018	1	-13	-10	-10	N/A
3/31/2018	1	-13	-10	-9	N/A
12/31/2017	0	-12	N/A	-9	N/A
9/30/2017	1	-12	N/A	-9	N/A
6/30/2017	1	-13	N/A	-8	N/A
3/31/2017	1	-12	N/A	-7	N/A
12/31/2016	1	-10	N/A	-6	N/A
9/30/2016	1	-7	N/A	-4	N/A
6/30/2016	1	-7	N/A	-5	N/A
3/31/2016	1	-6	N/A	-6	N/A
12/31/2015	1	-7	N/A	-7	N/A
3/31/2015	1	-10	N/A	-6	N/A
12/31/2014	1	-10	N/A	-6	N/A
12/31/2013	2	-6	N/A	-5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von BCDA über der Sparquote liegt (2.4%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von BCDA schneller wachsen werden als der Markt US

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von BCDA in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von BCDA schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von BCDA schneller wachsen werden als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von BCDA in 3 Jahren voraussichtlich hoch sein wird

BioCardia Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 74%, EPS upgraded

Consensus revenue estimates increase by 86%

Price target decreased by 24% to US$7.50

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$9.88

Recent updates

New major risk - Shareholder dilution

First quarter 2024 earnings released: US$0.09 loss per share (vs US$0.17 loss in 1Q 2023)

Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable

BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

BioCardia, Inc., Annual General Meeting, May 20, 2024

New major risk - Financial position

Full year 2023 earnings: EPS and revenues miss analyst expectations

BioCardia, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

BioCardia Receives Determination Letter from the Staff that the Company Fails to Regain Compliance with the MVLS Requirement

BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

New major risk - Market cap size

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $2.75 million.

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $1.3 million.

BioCardia, Inc. Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

New major risk - Negative shareholders equity

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

BioCardia, Inc. Elects Bill Facteau as Class I Director

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

Biocardia, Inc. Announces Completion of Enrollment in Phase Iii Cardiamp Hf Trial and Plans for Cardiamp Hf Trial Ii

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia, Inc. Announces Clarification and Next Steps on Its Autologous CardiAMP Cell Therapy Programs

Biocardia, Inc. Announces Interim Efficacy Results in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial

BioCardia, Inc., Annual General Meeting, Oct 18, 2023

Consensus revenue estimates decrease by 74%, EPS upgraded

New major risk - Revenue size

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

BioCardia, Inc. to Report First Half, 2023 Results on Aug 09, 2023

New major risk - Share price stability

Biocardia, Inc. Announces Dsmb Recommendation to Pause New Enrollment in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial While Additional Blinded Data Is Collected

BioCardia, Inc. Completes Submission of Cardiamp Cell Therapy System in Heart Failure to Japan's Pharmaceutical Medical Device Agency

New minor risk - Share price stability

Insider recently bought US$177k worth of stock

Consensus revenue estimates increase by 86%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

BioCardia, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 24% to US$7.50

BioCardia, Inc. announced that it expects to receive $3.564989 million in funding

BioCardia, Inc. Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$9.88

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

BioCardia, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Insufficient new directors

Biocardia®, Inc. to Present New Data from Cardiamp Cell Therapy for Heart Failure Pivotal Trial At the Heart Failure Society of America Annual Meeting

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

BioCardia stock rises on contract for delivery products for BlueRock's cell therapies

Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?

Consensus revenue estimates increase by 138%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

BioCardia, Inc. to Report First Half, 2022 Results on Aug 10, 2022

BioCardia, Inc. Announces US Patent on Imaging System for Targeting Cardiac Therapies

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 64%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation

BioCardia, Inc. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$10.63

Consensus forecasts updated

BioCardia, Inc. Announces FDA Approval of its IND for NK1R+ Mesenchymal Stem Cells